| EPA079 | Maternal HIV status and risk of infant M. tuberculosis infection | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA078 | Role of PD-1, TIGIT and TIM3 on NK cell exhaustion and function in HIV/HCV coinfection, and the impact of HCV elimination in the long term | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA077 | Active tuberculosis co-infection is associated with broad HIV-1 antibody responses | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA075 | What can we learn from the 2021 Aids Healthcare Foundation-Eswatini mortality profile after meeting the UNAIDS 95-95-95 target? | E-poster | HIV and co-morbidities |
| EPA074 | Youth HIV-associated neurocognitive disorders: a longitudinal cohort study | E-poster | HIV and co-morbidities |
| EPA073 | MiRNAs as cardiovascular risk biomarkers in people living with HIV (PWH) | E-poster | HIV and co-morbidities |
| EPA072 | Association of HIV viremia with pro-inflammatory fatty acid signatures in pregnancy | E-poster | HIV and co-morbidities |
| EPA071 | Scaling-up HPV testing for cervical cancer screening in WLHIV in Zambia | E-poster | HIV and co-morbidities |
| EPA070 | High adaptive NK cell frequencies reduce the risk of developing coronary atherosclerotic plaque in cytomegalovirus infected people living with HIV | E-poster | HIV and co-morbidities |
| EPA069 | Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |